GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » PE Ratio (TTM)

Lantheus Holdings (Lantheus Holdings) PE Ratio (TTM) : 14.13 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-28), Lantheus Holdings's share price is $65.56. Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.64. Therefore, Lantheus Holdings's PE Ratio (TTM) for today is 14.13.


The historical rank and industry rank for Lantheus Holdings's PE Ratio (TTM) or its related term are showing as below:

LNTH' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 4.07   Med: 22.83   Max: 239.5
Current: 14.13


During the past 13 years, the highest PE Ratio (TTM) of Lantheus Holdings was 239.50. The lowest was 4.07. And the median was 22.83.


LNTH's PE Ratio (TTM) is ranked better than
74.51% of 608 companies
in the Drug Manufacturers industry
Industry Median: 23.84 vs LNTH: 14.13

Lantheus Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $1.47. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.64.

As of today (2024-04-28), Lantheus Holdings's share price is $65.56. Lantheus Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $4.09. Therefore, Lantheus Holdings's PE Ratio without NRI for today is 16.04.

During the past 13 years, Lantheus Holdings's highest PE Ratio without NRI was 237.26. The lowest was 5.98. And the median was 21.09.

Lantheus Holdings's EPS without NRI for the three months ended in Dec. 2023 was $1.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $4.09.

During the past 12 months, Lantheus Holdings's average EPS without NRI Growth Rate was 805.50% per year.

During the past 13 years, Lantheus Holdings's highest 3-Year average EPS without NRI Growth Rate was 108.30% per year. The lowest was -22.50% per year. And the median was 33.65% per year.

Lantheus Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $1.52. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.79.


Lantheus Holdings PE Ratio (TTM) Historical Data

The historical data trend for Lantheus Holdings's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings PE Ratio (TTM) Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.96 At Loss At Loss 127.40 13.33

Lantheus Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.40 At Loss 204.68 48.59 13.33

Competitive Comparison of Lantheus Holdings's PE Ratio (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's PE Ratio (TTM) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's PE Ratio (TTM) falls into.



Lantheus Holdings PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Lantheus Holdings's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=65.56/4.640
=14.13

Lantheus Holdings's Share Price of today is $65.56.
Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.64.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Lantheus Holdings  (NAS:LNTH) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Lantheus Holdings PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (Lantheus Holdings) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker officer: Senior Vice President, Quality C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao officer: Chief Human Resources Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862